Get the Stockscreener App
10.11
0.80%
0.06
Prothena Corporation Plc stock is traded at $10.11, with a volume of 86,382.
It is up +0.80% in the last 24 hours and up +23.39% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$10.05
Open:
$10.03
24h Volume:
86,382
Relative Volume:
0.10
Market Cap:
$546.13M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-10.11
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+2.74%
1M Performance:
+23.39%
6M Performance:
-0.88%
1Y Performance:
-41.17%
1-Day Range:
$10.01
$10.21
1-Week Range:
$9.9203
$10.65
52-Week Range:
$4.32
$18.88
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
10.15 | 540.99M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.52 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
What does recent volatility data suggest for Prothena Corporation plc2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
Live market analysis of Prothena Corporation plcJuly 2025 Intraday Action & Daily Stock Trend Reports - newser.com
Tools to monitor Prothena Corporation plc recovery probabilityOptions Play & Long-Term Capital Growth Ideas - newser.com
Why Prothena Corporation plc stock is seen as undervaluedMarket Performance Report & Daily Stock Momentum Reports - newser.com
FY2029 EPS Estimates for Prothena Boosted by HC Wainwright - MarketBeat
Prothena Corporation plc stock volume spike explained2025 Top Decliners & Community Consensus Trade Signals - newser.com
What data driven models say about Prothena Corporation plc’s futureMarket Weekly Review & Low Drawdown Trading Techniques - newser.com
What analysts say about Prothena Corporation plc stockAnalyst Downgrades & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Prothena stock price target raised to $20 from $14 at H.C. Wainwright - Investing.com Nigeria
Prothena Corp. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Public Employees Retirement System of Ohio Invests $256,000 in Prothena Corporation plc $PRTA - Defense World
Prothena Corp (PRTA) Sees Raised Price Target by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Is now a turning point for Prothena Corporation plcBull Run & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-05 07:33:52 - newser.com
Leading vs lagging indicators on Prothena Corporation plc performance2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Evaluating Prothena Corporation plc with trendline analysisWeekly Trade Review & Daily Profit Maximizing Tips - newser.com
Published on: 2025-10-03 05:55:14 - newser.com
How moving averages guide Prothena Corporation plc tradingJuly 2025 Summary & Free Technical Confirmation Trade Alerts - newser.com
Prothena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986 - PharmiWeb.com
Prothena's partner Bristol Myers Squibb obtains fast track designation from US FDA for BMS-986446 for treatment of Alzheimer's disease - MarketScreener
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease - Business Wire
Hopeful Week For Insiders Who Bought US$2.75m Of Prothena Stock - 富途牛牛
Published on: 2025-09-30 03:25:21 - newser.com
Published on: 2025-09-29 17:23:52 - newser.com
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corporation Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
0.11%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):